IN8bio, Inc. (NASDAQ:INAB) Short Interest Up 768.0% in February

IN8bio, Inc. (NASDAQ:INAB) was the recipient of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 3,760,000 shares, a growth of 768.0% from the January 31st total of 433,200 shares. Based on an average trading volume of 4,930,000 shares, the short-interest ratio is currently 0.8 days. Approximately 6.5% of the shares of the stock are short sold.

IN8bio Trading Down 4.9 %

Shares of NASDAQ:INAB opened at $0.25 on Friday. The firm has a market capitalization of $18.37 million, a price-to-earnings ratio of -0.34 and a beta of 0.05. The business’s 50 day moving average price is $0.28 and its 200-day moving average price is $0.33. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.84 and a quick ratio of 1.84. IN8bio has a 1 year low of $0.22 and a 1 year high of $1.74.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of IN8bio in a report on Wednesday, February 12th.

Hedge Funds Weigh In On IN8bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sigma Planning Corp increased its stake in shares of IN8bio by 42.0% during the third quarter. Sigma Planning Corp now owns 851,280 shares of the company’s stock worth $230,000 after purchasing an additional 251,600 shares in the last quarter. BIOS Capital Management LP acquired a new position in shares of IN8bio during the fourth quarter valued at approximately $2,212,000. AIGH Capital Management LLC lifted its position in shares of IN8bio by 269.7% in the fourth quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock valued at $1,593,000 after acquiring an additional 4,517,227 shares in the last quarter. Franklin Resources Inc. acquired a new stake in shares of IN8bio in the fourth quarter worth approximately $1,465,000. Finally, Geode Capital Management LLC boosted its stake in shares of IN8bio by 56.5% in the fourth quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock worth $133,000 after acquiring an additional 185,919 shares during the last quarter. 92.05% of the stock is owned by hedge funds and other institutional investors.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.